Last reviewed · How we verify
Eybelis ophthalmic solution 0.002%
Eybelis is a selective rho kinase inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.
Eybelis is a selective rho kinase inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Eybelis ophthalmic solution 0.002% |
|---|---|
| Also known as | Omidenepag isopropyl ophthalmic solution |
| Sponsor | Santen Pharmaceutical Asia Pte. Ltd. |
| Drug class | Rho kinase (ROCK) inhibitor |
| Target | ROCK1/ROCK2 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Rho kinase inhibitors work by blocking the Rho-associated coiled-coil containing protein kinase (ROCK), which leads to relaxation of the trabecular meshwork and Schlemm's canal, thereby improving aqueous humor drainage. This mechanism reduces intraocular pressure in glaucoma and ocular hypertension patients. Netarsudil, the active ingredient in Eybelis, is a selective ROCK inhibitor administered as a topical ophthalmic solution.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Corneal verticillata
- Conjunctival blanching
- Eye irritation
- Instillation site pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: